High fetal hemoglobin level is the most important predictor of favorable clinical outcome in sickle cell disease. We carried out a genome-wide association study (GWAS) on estimated fetal beta globin RNA expression ratio (FGR) using blood RNA sequence data from 22,093 adult Icelanders. In addition to the well-known BCL11A, HBB/HBG2 and HBS1L-MYB loci, we found 33 loci associated with FGR conditioned on variants at these 3 loci (cFGR). We identified fourteen candidate causal genes at the 33 loci. In the ZBTB7A, GFI1B, ZFPM1, and ALAS2 genes we identified rare loss-of-function variants that associate with large effect on cFGR. A rare variant in ZBTB7A, which had the largest increasing effect on cFGR, generates an alternative upstream inframe ATG in an erythroid specific transcript encoding an addition of 119 amino acids to the protein, highlighting a potential therapeutic target. Furthermore, rare variants with large effects in ALAS2 and GFI1B implicate the heme biosynthesis pathway and isoform specific role of GFI1B in fetal hemoglobin regulation.